PTC Therapeutics, Inc. (PTCT) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, PTC Therapeutics reported revenue of $1.73B, up 114.5% from $806.8M the year before. Net income was $682.6M (a 39.4% net margin), or $7.78 per diluted share. Operating margin was 50.1%. Operating activities generated $711.2M of cash, leaving $702.3M of free cash flow. At fiscal year end, PTC Therapeutics held $2.90B in total assets against $3.10B in total liabilities, including $984.6M of cash and equivalents.
Open the full interactive PTC Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
PTC Therapeutics Key Stats
| Share Price | $59.92 |
|---|---|
| Market Cap | $5.51B |
| P/E Ratio | 7.7 |
| Revenue YoY Growth | +114.5% |
| 52-Week Range | $59.92 – $89.55 |
| Shares Outstanding | 83.0 million (basic, 2026 Q2) |
PTC Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $380.8M | $538.6M | $698.8M | $937.8M | $806.8M | $1.73B |
| Operating Income | -$431.8M | -$374.4M | -$447.4M | -$439.5M | -$302.6M | $866.9M |
| Pre-Tax Income | -$402.9M | -$518.3M | -$587.5M | -$696.1M | -$363.1M | $696.6M |
| Income Tax | $35.2M | $5.6M | -$28.5M | -$69.5M | $176,000 | $14.0M |
| Net Income | -$438.2M | -$523.9M | -$559.0M | -$626.6M | -$363.3M | $682.6M |
| Diluted EPS | -$6.64 | -$7.43 | -$7.79 | -$8.37 | -$4.73 | $7.78 |
PTC Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $211.0M | $164.7M | $272.6M | $360.5M |
| Net Income | $15.9M | -$135.0M | -$2.8M | $83.5M |
| Diluted EPS | $0.20 | -$1.53 | -$0.03 | $0.92 |
PTC Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $208.8M | $189.7M | $279.8M | $594.0M | $779.7M | $984.6M |
| Current Assets | $1.23B | $954.4M | $693.8M | $1.22B | $1.37B | $2.27B |
| Total Assets | $2.21B | $1.94B | $1.71B | $1.90B | $1.71B | $2.90B |
| Current Liabilities | $277.3M | $509.3M | $406.2M | $603.1M | $581.0M | $968.4M |
| Total Long-Term Debt | $309.1M | $431.4M | $571.7M | $284.2M | $285.4M | $286.6M |
| Total Liabilities | $1.73B | $1.94B | $2.05B | $2.71B | $2.80B | $3.10B |
| Shareholders' Equity | $482.0M | $1.4M | -$347.1M | -$818.6M | -$1.10B | -$205.3M |
PTC Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$194.1M | -$251.3M | -$356.7M | -$158.4M | -$107.7M | $711.2M |
| Cash From Investing | -$561.5M | $219.2M | $290.2M | -$176.7M | $44.2M | -$862.0M |
| Cash From Financing | $668.7M | $20.9M | $168.0M | $646.4M | $255.9M | $331.1M |
| Free Cash Flow | -$211.9M | -$279.5M | -$388.7M | -$186.9M | -$114.2M | $702.3M |
Figures from PTC Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full PTC Therapeutics financials page for every line item.
PTC Therapeutics Company Profile
| Ticker | PTCT |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Warren, New Jersey |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001070081 |
Frequently Asked Questions
What was PTC Therapeutics' revenue in fiscal 2025?
PTC Therapeutics (PTCT) reported revenue of $1.73B for fiscal 2025.
What is PTC Therapeutics' annual revenue history?
PTC Therapeutics' annual revenue by fiscal year: 2020: $380.8M; 2021: $538.6M; 2022: $698.8M; 2023: $937.8M; 2024: $806.8M; 2025: $1.73B.
What was PTC Therapeutics' net income in fiscal 2025?
PTC Therapeutics reported net income of $682.6M for fiscal 2025.
What was PTC Therapeutics' earnings per share (EPS) in fiscal 2025?
PTC Therapeutics' diluted EPS was $7.78 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did PTC Therapeutics generate in fiscal 2025?
PTC Therapeutics generated $702.3M of free cash flow in fiscal 2025.
What was PTC Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), PTC Therapeutics reported revenue of $360.5M.
How much debt does PTC Therapeutics have?
PTC Therapeutics reported $286.6M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of PTC Therapeutics are outstanding?
PTC Therapeutics reported a weighted average of 83.0 million basic shares outstanding in 2026 Q2.
What is PTC Therapeutics' market cap?
Based on its latest closing price, PTC Therapeutics (PTCT) has a market capitalization of about $5.51B.
When does PTC Therapeutics' fiscal year end?
PTC Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is PTC Therapeutics headquartered?
PTC Therapeutics lists its business address in Warren, New Jersey in its SEC filings.